Subscribe
Be the first with the news that moves the market- VIVO Cannabis (VIVO) has obtained a final court order approving its acquisition by MediPharm Labs
- The arrangement is expected to be completed by the end of Q1 2023, subject to certain closing conditions
- VIVO’s common shares and warrants are expected to be delisted from the TSX within two to three business days following the completion of the arrangement
- VIVO Cannabis is a Canadian cannabis company with production, sales, and research licenses from Health Canada
- VIVO Cannabis (VIVO)
VIVO (VIVO) has been approved by the Ontario Superior Court of Justice to be acquired by MediPharm.
The arrangement was previously approved at a special meeting of VIVO’s shareholders on March 21, 2023, and is expected to become effective by the end of Q1 2023, subject to customary closing conditions.
Following the completion of the arrangement, VIVO’s common shares and warrants will be delisted from the TSX within two to three business days.
The details of the arrangement can be found in the joint management information circular by VIVO and MediPharm dated February 6, 2023.
VIVO Cannabis is a Canadian cannabis company that holds production, sales and research licenses from Health Canada. It is also developing an international presence in Germany and Australia.
VIVO Cannabis (VIVO) opened today at $0.02.
